vrataurala
   ABIO Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
ARCA biopharma is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. Co.'s key product candidate, Gencaro™ (bucindolol hydrochloride), is a pharmacological beta-blocker and mild vasodilator that Co. is developing for the treatment of patients with atrial fibrillation, and chronic heart failure with reduced left ventricular ejection fraction. Co. also has pharmacogenetic and other patent rights to drug candidates that have potential indications in cardiovascular disease, oncology and other therapeutic areas, in both early and later stages of development. According to our ARCA biopharma stock split history records, ARCA biopharma has had 3 splits.
ARCA biopharma stock split history picture
ARCA biopharma (ABIO) has 3 splits in our ARCA biopharma stock split history database. The first split for ABIO took place on January 28, 2009. This was a 1 for 20 reverse split, meaning for each 20 shares of ABIO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split. ABIO's second split took place on March 05, 2013. This was a 1 for 6 reverse split, meaning for each 6 shares of ABIO owned pre-split, the shareholder now owned 1 share. For example, a 50 share position pre-split, became a 8.33333333333333 share position following the split. ABIO's third split took place on September 04, 2015. This was a 1 for 7 reverse split, meaning for each 7 shares of ABIO owned pre-split, the shareholder now owned 1 share. For example, a 8.33333333333333 share position pre-split, became a 1.19047619047619 share position following the split.

When a company such as ARCA biopharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the ARCA biopharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1.19047619047619 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ARCA biopharma shares, starting with a $10,000 purchase of ABIO, presented on a split-history-adjusted basis factoring in the complete ARCA biopharma stock split history. ARCA biopharma split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 11/18/2008
End date: 11/16/2018
Start price/share: $226.80
End price/share: $0.56
Dividends collected/share: $0.00
Total return: -99.75%
Average Annual Total Return: -45.14%
Starting investment: $10,000.00
Ending investment: $24.69
Years: 10.00
Date Ratio
01/28/20091 for 20
03/05/20131 for 6
09/04/20151 for 7
ABIO is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ABMD Split History
ABT Split History
ABV Split History
ACER Split History
ACET Split History
ACHC Split History
ACHV Split History
ACST Split History
ACUR Split History
ADK Split History

Also explore: ABIO shares outstanding history


More latest
Latest
Latest
Funds Holding ARCA biopharma
ARCA biopharma Insider Buying